AngioDesign
Pre-clinicalAngioDesign focuses on the rational design of enhanced, next-generation drugs for proven disease targets and its first target is Angiotensin-Converting Enzyme (ACE). AngioDesign is using 3-D structure-guided design to synthesize a new class of domain-selective ACE inhibitors, alone and in combination with other inhibitors, for cardiovascular and other non-communicable diseases.
About
AngioDesign focuses on the rational design of enhanced, next-generation drugs for proven disease targets and its first target is Angiotensin-Converting Enzyme (ACE). AngioDesign is using 3-D structure-guided design to synthesize a new class of domain-selective ACE inhibitors, alone and in combination with other inhibitors, for cardiovascular and other non-communicable diseases.
Funding History
2Total raised: $5M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile